OPKO Health
| Company type | Public |
|---|---|
| NYSE: OPK TASE: OPK | |
| Industry | Medical Appliances & Equipment |
| Founded | 1991  |
| Headquarters | Miami, Florida. |
| Products | Medical Products |
| Website | www |
OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals.[1] The company develops treatments for secondary hyperparathyroidism, and has recently finished the patient recruitment for a Phase III trial against insufficiency in Vitamin D.[2] The company is a publicly traded company on NYSE under the symbol "OPK". It acquired Laboratorio Arama de Uruguay in 2014 and is seeking to expand its presence in Uruguay and Argentina.[1]
History
OPKO Health Incorporation focuses on production of cardiovascular products, vaccines, hormones, antibiotics, gastrointestinal products, and eye care. The company operates in the U.S., Chile, Israel, Mexico, Uruguay, and Spain.[3]
Production
The productions of OPKO Health Incorporation include mainly two segments: Pharmaceuticals and Diagnostics.[4] The company is recently expanding collaboration with Bristol-Myers Squibb Co. on diagnostic test technology, which involves blood tests identifying biomarkers of diseases.[5]
Corporate affairs
In December 2013 OPKO Health completed the sale of its stake in Sorrento Therapeutics.[6] The company entered into a stock purchase agreement with Sorrento in 2009.
Stocks
The ticker symbol for OPKO Health Incorporation is "OPK", under which the company went public on NYSE.[7]
References
- ^ a b Uruguay March 2014 Florida Trend
- ^ "OPKO Finishes Patient Recruitment In Second Phase 3 Study Of Rayaldy". Retrieved Dec 26, 2013.
- ^ "History". Retrieved Dec 20, 2013.
- ^ "Business Summary". Retrieved Dec 22, 2013.
- ^ "Opko Expands Technology Collaboration With Bristol-Myers". Retrieved Dec 25, 2013.
- ^ "OPKO Health Sells Remainder of Sorrento Therapeutics Stake".
- ^ "Business Summary". Retrieved Dec 22, 2013.
